

# Radiation Therapy

## Adjudication Guideline

**Rule Category:**  
Medical

**Ref: No:**  
2013-MN-0024

**Version Control:**  
Version No. 3.0

**Effective Date:**  
01/12/2013

**Revision Date:**  
31/12/2024

**Approved by:**  
Daman

**Responsible:**  
Medical Standards  
& Research

**Related Adjudication  
Guidelines:**  
N/A

## Table of Contents

1.	Abstract.....	3
1.1	For Members .....	3
1.2	For Medical Professionals .....	3
2.	Scope.....	3
3.	Adjudication Policy .....	4
3.1	Eligibility / Coverage Criteria .....	4
3.2	Requirements for Coverage.....	6
3.3	Non-Coverage.....	6
3.4	Payment and Coding Rules.....	6
4.	Denial Codes.....	8
5.	Appendices .....	9
5.1	References .....	9
5.2	Revision History .....	9

## 1. Abstract

### 1.1 For Members

- Radiation therapy also known as radiotherapy is the medical use of beams of radiation, to destroy or damage cancer cells, which prevents these cells from multiplying with little harm to nearby healthy tissues. Radiotherapy is usually given as a series of treatments over several days or weeks. Each treatment is known as a fraction. Radiation therapy can be given as external radiation, as internal radiation, or as systemic radiation. In some cases, more than one type is used. Sometimes radiotherapy is used in addition to another main treatment like surgery or chemotherapy.
- Daman covers radiation therapy if medically indicated as per best medical practice standards and as per the policy terms and conditions of each health insurance plan administered by Daman.

### 1.2 For Medical Professionals

- Radiation therapy involves treating cancerous disease with penetrating beams of high-energy radiation which works by depositing energy within the cells of the treated area. This causes irreparable damage to the cell's DNA. Sensitivity to Radiotherapy varies with different tumour types which is why a range of doses and schedules are used. The process of Radiotherapy is complex and involves understanding the principles of medical physics, radiobiology, radiation safety, dosimetry, radiation treatment planning, simulation and interaction of radiation with other treatment modalities. There are lifetime dose limits of radiation. Radiotherapy is recommended for those patients in whom the benefits outweigh the possible side effects. The length of the treatment course depends on site, size and type of the cancer.
- Daman covers radiation therapy if medically indicated as per best medical practice standards and as per the policy terms and conditions of each health insurance plan administered by Daman.

## 2. Scope

- The AR defines the appropriate criteria for the delivery of external and internal types of radiotherapy. It covers the documentation requirements to support clinical superiority of radiotherapy methods. The AR focuses only on radiotherapy for cancerous disease. Different modalities of radiotherapy used for cancer treatment are:
  - External beam radiotherapy (EBRT)
  - Internal radiotherapy (Brachytherapy)

## 3. Adjudication Policy

### 3.1 Eligibility / Coverage Criteria

- Daman covers radiotherapy services that are medically reasonable and necessary as per the indications given below:
- **Common Indications of Radiotherapy:** (EBRT and Brachytherapy)
  - Head and neck tumours
  - Brain and Spinal tumours
  - Thoracic and abdominal malignancies
  - Pelvic and retroperitoneal tumours
  - Breast cancer
  - Prostate cancer
- **Indications specific to external beam therapy techniques:** (in addition to common indications)
  - **SRS indications:**
    - Primary malignancies of the central nervous system for lesions <5cm.
    - Metastatic brain or spinal lesions, with stable systemic disease, Karnofsky Performance Status 40 or greater and other reasonable survival expectations, or ECOG status of 3 or less
    - Primary and secondary malignant tumours of brain, single and multiple, residual tumour cells following surgery, intracranial, orbital and base-of-skull tumours with immediately adjacent bony structures.
  - **SBRT indications:**
    - Tumours of any type arising in or near previously irradiated regions
    - Recurrent pelvic, head and neck tumours after primary irradiation when and only each of the following criteria are met, and each specifically documented in the medical record:
      - The patient's general medical condition (notably, the performance status) justifies aggressive treatment to the cancer
      - The tumour burden can be completely targeted with acceptable risk to critical normal structures
  - **Intensity modulated radiation therapy (IMRT) indications:**
    - Left sided breast cancer with proximity to critical cardiac and pericardial structures (less frequently necessary for tumours of the right breast)
    - Primary, metastatic tumours of the spine where the spinal cord tolerance may be exceeded with conventional treatment
    - IMRT may also be beneficial for treating paediatric malignancies.
    - Re-irradiation of regions listed in indications. Intensity modulated radiation therapy (IMRT) is considered medically necessary and, therefore, covered when all the following criteria are met:

- IMRT is not a replacement for conventional or three-dimensional conformal radiation therapy.
- Sparing surrounding normal tissue is of added benefit.
- **Particle beam therapy indications**
  - **Proton beam therapy (PBT)** is indicated:
    - For spinal tumours and tumours at the base of the skull.
    - To reduce the risks of late effects, including second cancers and cardiovascular risk, which are particularly relevant when treating children and young adults.
  - **Neutron beam therapy (NBT)** may be appropriate for the following sites, depending on stage and histology:
    - Prostate tumours
    - Bulky T2, or T3 or T4 tumours
    - Soft tissue tumours
    - Bone and cartilage tumours
    - Large tumours and metastatic neutron-sensitive tumours
    - Melanoma.
- **Indications specific to brachytherapy** (in addition to common indications)
  - Appropriate for men who have low risk early-stage prostate cancer disease.
  - Skin cancer
  - Soft tissue sarcoma
  - Brachytherapy is indicated in certain clinical scenarios:
    - Retreatment of previously treated areas
    - As a boost to external treatment
- **Documentation Requirements**
  - The medical records should reflect the medical necessity and appropriateness of the diagnostic and/or therapeutic services provided along with the site of service. The radiation oncology reports should include:
    - Standard history and physical, patient's functional status.
    - The TNM classification of the tumour(s) and the staging (if available).
    - Current performance status (Karnofsky Performance Status or ECOG Performance Status).
    - Results of diagnostic tests
    - Treatment options, including the intent of therapy (e.g., cure, adjuvant, palliation, local control). Also document the risks/benefits and prognosis.
    - Treatment planning, management/delivery should be documented by radiology oncologist.
    - Treatment dates and treatment status (course of therapy completed, changed or suspended).
    - The treatment summary key elements should include the External Beam application or Brachytherapy application.

## 3.2 Requirements for Coverage

- ICD and CPT codes must be coded to the highest level of specificity.

## 3.3 Non-Coverage

- When the documentation does not meet the criteria for the service rendered, such services will be denied as not reasonable and necessary.
- Follow-up visits for 90 days are not separately covered for brachytherapy.
- Patients who have had transurethral prostatic resection (TURP) previously are not eligible for the brachytherapy procedure because complication rates are increased.
- Traditional “field-in-field technique,” which is neither MLC (Multi-leaf collimator) nor compensator-based, is not considered IMRT but rather external beam therapy.
- Proton beam therapy is not covered for cancers that are widely disseminated, have haematogenous metastases, or as a short-term palliative procedure.

## 3.4 Payment and Coding Rules

- Please apply Regulator payment rules and regulations and relevant coding manuals for ICD, CPT, etc.
- Note: ICD codes for encounter for radiation therapy (V58.0/ Z51.0) should only be used as principal diagnosis, followed by the reason of radiation therapy as a secondary diagnosis.
- Current Procedural Terminology (CPT) listings for external beam therapy and brachytherapy include initial consultations, clinical treatment planning, simulation, medical radiation physics, dosimetry, treatment devices, special services, and clinical treatment management procedures. They include normal follow-up care during course of treatment and for three months following its completion.
- **General Rules**
  - Consultation: Clinical Management Preliminary consultation, evaluation of patient prior to decision to treat, or full medical care (in addition to treatment management) when provided by the treatment radiologist may be identified by the appropriate procedure codes from Evaluation and Management, Medicine or Surgery sections.
- **Frequency of Service**
  - Each patient’s condition and response to treatment must medically warrant the number of services reported for payment. Patients usually receive radiation treatments once a day, five days a week for a total of two to nine weeks. The patient's diagnosis determines the total duration of treatment. Occasionally, treatments are given twice a day. Frequency more than this value will require supporting documentation.

- Radiation treatment that exceeds 5 sessions is not covered as SBRT.
- SRS is 1 fraction in the brain.
- In most ocular cancers, the total dose of proton beam radiation is divided into daily fractions (usually given Monday thru Friday) over several weeks.
- Brachytherapy is delivered in 3-5 treatments. 10 separate HDR brachytherapy treatments over one or more weeks may be delivered.

## • Adjudication Examples

### ○ Example 1

- **Question:** A claim received with SBRT Treatment delivery and Other Radiation Treatment delivery). Is it appropriate to pay this claim?
- **Answer:** No, as per the CPT guidelines, SBRT treatment delivery should not be used in conjunction with Other Radiation Treatment delivery.

### ○ Example 2

- **Question:** A patient has undergone brachytherapy in which X-rays are used for the simulation. The claim has been submitted with radiology port films. Is it appropriate to approve the claim?
- **Answer:** No, this claim should be rejected, although x-rays may be used in brachytherapy simulation, but should not be reported as port films.

### ○ Example 3

- **Question:** A 50-year-old man with prostate cancer is recommended to undergo a Proton beam radiation therapy using 2 isocentres. Claim is submitted with the CPT code for the same. Is it appropriate to approve the claim?
- **Answer:** Yes, since the therapy is done using isocentres.

### ○ Example 4

- **Question:** A patient has undergone a conventional clinical treatment planning and IMRT treatment planning on the same day. A claim is submitted with the CPT code for IMRT treatment planning only. Is it appropriate to approve the claim?
- **Answer:** Yes, it is payable. As per the coding guidelines, IMRT treatment planning includes any kind of treatment planning.

## 4. Denial Codes

Code	Code Description
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities
NCOV-003	Service(s) is (are) not covered
PRCE-002	Service is included in another service paid
NCOV-001	Diagnosis(es) is (are) not covered



## 5. Appendices

### 5.1 References

- <https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/ASTROSBRTModelPolicy.pdf>
- [https://www.uptodate.com/contents/radiation-therapy-techniques-in-cancer-treatment?search=radiation%20therapy&source=search\\_result&selectedTitle=1%7E150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/radiation-therapy-techniques-in-cancer-treatment?search=radiation%20therapy&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1)
- <https://www.astro.org/patient-care-and-research/clinical-practice-statements/clinical-practice-guidelines>
- <https://www.iaea.org/topics/cancer-treatment-brachytherapy>
- [https://www.uptodate.com/contents/brachytherapy-for-low-risk-or-favorable-intermediate-risk-clinically-localized-prostate-cancer?search=brachytherapy&source=search\\_result&selectedTitle=1%7E150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/brachytherapy-for-low-risk-or-favorable-intermediate-risk-clinically-localized-prostate-cancer?search=brachytherapy&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1)
- [https://www.facs.org/media/fr0phnbd/case-studies-for-coding-radiation-treatment-v4-0-20220519064258\\_496407.pdf](https://www.facs.org/media/fr0phnbd/case-studies-for-coding-radiation-treatment-v4-0-20220519064258_496407.pdf)
- <https://pmc.ncbi.nlm.nih.gov/articles/PMC7548033/>
- <https://www.astro.org/practice-support/reimbursement/practice-management-resources/basics-of-coding>

### 5.2 Revision History

Date	Change(s)
01/11/2013	V1.0 <ul style="list-style-type: none"> <li>• Published</li> </ul>
15/07/2014	V2.0 <ul style="list-style-type: none"> <li>• Updated as per the system requirement</li> <li>• Payment and billing rules updated</li> </ul>
31/12/2024	V3.0 <ul style="list-style-type: none"> <li>• Updated as per the system requirement</li> <li>• Template Updated</li> <li>• References Updated</li> </ul>

#### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.